



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

25th June 2026

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that the Company has received a Demand Notice dated 24th June 2026 from the National Pharmaceutical Pricing Authority. The relevant details to be disclosed are as under:

Sr no	Particulars	Details
1	Name of the authority	National Pharmaceutical Pricing Authority
2	Nature and details of the action(s) taken, initiated or order(s) passed	Demand Notice dated 24 th June 2026 Total Demand Rs. 3,54,12,025/- (Alleged overcharging-Rs.1,22,91,163;Interest-2,31,20,862)
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	24 th June 2026
4	Details of violation(s) / contravention(s) committed or alleged to be committed	Overcharged in the sale of scheduled formulations by charging price higher than the price fixed / notified by the Government / NPPA in the relevant period.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No impact on financial operations of the Company. The Company would be filing an appeal against demand order.

Kindly take the same on the record.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151